2015-06-02T08:00:45
START Is STOPPED: Study Confirms HIV Treatment Is Beneficial for All, Even Those with High CD4-Cell Counts In HIV and ID Observations, Dr. Paul Sax weighs in on the early conclusion of the START study. The early end to the Strategic Timing of Antiretroviral Treatment study proves that it's better to be on HIV treatment than to wait, even for those with normal CD4-cell counts and no symptoms. Why was deferring treatment a common strategy? In HIV and ID Observations, Dr. Paul Sax lists some reasons, most of which are irrelevant or have been disproven over time